<DOC>
	<DOCNO>NCT00453102</DOCNO>
	<brief_summary>Zevalin may effective therapy newly diagnose marginal zone lymphoma ( MZL ) .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan Rituximab Treating Patients With Previously Untreated Marginal Zone Lymphoma</brief_title>
	<detailed_description>This phase II study assess clinical response rate Ibritumomab Tiuxetan patient untreated nodal , splenic non-gastric extranodal MZL well antibiotic resistant patient mucosa-associated lymphoid tissue ( MALT ) gastric lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>≥ 18 year old previously untreated , histologically confirm Marginal Zone Lymphoma ( nongastric extranodal MZL , splenic MZL nodal MZL ) gastric MZL respond antibiotic therapy give 6 month prior enrollment , less 2 month ) Measurable evaluable disease All stag eligible Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 ( Appendix B ) Willing able provide write informed consent Women childbearing potential must negative pregnancy test study entry must agree use effective contraception treatment 6 month treatment Life expectancy least 6 month Prior chemotherapy , radiation therapy , immunotherapy , systemic corticosteroid , systemic biologic anticancer therapy begin study treatment . ≥ 25 % lymphoma bone marrow involvement Platelet count &lt; 100,000 cells/mm³ Neutrophil count &lt; 1,500 cells/mm³ Known history HIV infection Pregnant lactating ( pregnancy test require female patient childbearing potential ) Woman childbearing potential sexually active man unwilling use adequate contraceptive protection . Physical mental condition make patient unable complete specify followup assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>Non-gastric extranodal Marginal Zone Lymphoma</keyword>
	<keyword>Splenic Marginal Zone Lymphoma</keyword>
	<keyword>Nodal Marginal Zone Lymphoma</keyword>
	<keyword>Gastric Marginal Zone Lymphoma</keyword>
	<keyword>MZL</keyword>
	<keyword>Non-gastric extranodal MZL</keyword>
	<keyword>Splenic MZL</keyword>
	<keyword>Nodal MZL</keyword>
	<keyword>Gastric MZL</keyword>
</DOC>